Editas medicine stock price.

See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Editas medicine stock price. Things To Know About Editas medicine stock price.

Today's High Today's Low 52 Week High 52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. >> Main navigation. Research and Pipeline; CRISPR Gene EditingWhat happened. Shares of Editas Medicine ( EDIT 2.28%) were up 13.9% this week as of the market close on Thursday. Most of this big gain came after a key announcement from the company on Wednesday ...Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $).

What's more, shares of CRISPR Therapeutics (CRSP-6.39%) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (EDIT-6.64%) also saw its equity rise in price by a healthy ...Current Price. $10.49. Price as of November 22, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.

Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.CAMBRIDGE, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial ...

Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT). Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 51.5% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...For example, Editas Medicine (EDIT 11.37%) and Exact Sciences (EXAS 7.07%) fell by 66.5% and 36.4% respectively over the course of 2022. Since the change in the calendar year, Editas stock has ...

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Nov 29, 2023 · The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $3.19 above the current market price. The public float for EDIT is 81.05M and currently, short sellers hold a 19.58% of that float. On November 29, 2023, EDIT’s average trading volume was 1.64M shares. EDIT) stock’s latest price update

With Editas Medicine stock trading at $6.26 per share, the total value of Editas Medicine stock (market capitalization) is $511.02M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.Nov 17, 2023 · Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments What's more, shares of CRISPR Therapeutics (CRSP-6.39%) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (EDIT-6.64%) also saw its equity rise in price by a healthy ...Shares of Editas Medicine (EDIT 3.66%) ... which have yet to be adequately reflected in stock prices. Of course, the flip side is that the merger doesn't make as much sense for Beam Therapeutics. ...Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.

Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.Editas Medicine (EDIT 0.86%) and Bluebird Bio (BLUE 2.64%) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%.Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... What happened. Shares of Editas Medicine ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics.What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908.Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...

Moreover, the 36-month beta value for EDIT is 1.79. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 8 as “hold,” and 1 as “sell.” The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $5.41 above the current market price.

Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Phil Nadeau’s Buy rating for Editas Medicine’s stock is premised on a variety of factors. Key among these is the company’s strong financial position, with reported cash reserves of $446 ...Research Editas Medicine's (Nasdaq:EDIT) stock key valuation metrics while comparing it with its industry peers & market side by side. ... The above table shows the analyst EDIT forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$10 ...With Editas Medicine stock trading at $10.49 per share, the total value of Editas Medicine stock (market capitalization) is $856.76M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 19.25% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.27. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.48. Year to date, Editas ...See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 17.81% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.06 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $13.94 and as low as $6.08. Year to date, Editas ...CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.Nov 24, 2023 · Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

What's more, shares of CRISPR Therapeutics (CRSP-6.39%) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (EDIT-6.64%) also saw its equity rise in price by a healthy ...

What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...

Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis. Editas Medicine Inc. Real-Time Quotes. 10.68. BATS BZX Real-Time Price. As of 3:23pm ET. +0.15 / +1.42%. Today’s Change. 6.08. Today ||| 52-Week Range.Jun 15, 2023 · CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 46.41% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.83 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.The stock bounced back a bit toward the end of the day but was still down as much as 13.8% by 2 p.m. EST. Editas has a 52-week low of $9.59 and a 52-week high of $37.50, and is down more than 60% ...May-11-23 10:32AM. Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress. (GlobeNewswire) May-10-23 06:02AM. Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%. (Simply Wall St.)Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.

Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's EDIT shares and potentially its market environment …Editas Medicine saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 16,770,000 shares, an increase of 2.1% from the previous total of 16,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are ...Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...Instagram:https://instagram. vti stokcwhat is the value of kennedy half dollarscollector's insuranceprsnx Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Oct 2, 2023 · Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. By Alex Carchidi – Oct 2, 2023 at 10:00AM ... Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET. eafaxapple dividend payment 1. Editas Medicine Editas Medicine is a biotech company that focuses on gene-editing therapies. Like many of its peers in this niche, Editas Medicine currently has no approved products and isn't ...Editas Medicine stock quote and company news. Get the latest EDIT company stock news & quotes. td ameritrade for dummies Jun 6, 2021 · For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908. Editas Medicine Inc stock price live 10.42, this page displays NASDAQ EDIT stock exchange data. View the EDIT premarket stock price ahead of the market session or …Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...